ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed

Simply Wall St.

03/21

In March 2026, ImmunityBio reported that the National Comprehensive Cancer Network updated its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2621876759"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621876759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621876759?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-21 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621876759","market":"nz","top_or_hot":-1,"title":"ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>In March 2026, ImmunityBio reported that the National Comprehensive Cancer Network updated its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-128-after-nccn-expands-anktiva-bladde\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-03-21 02:14</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>In March 2026, ImmunityBio reported that the National Comprehensive Cancer Network updated its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-128-after-nccn-expands-anktiva-bladde\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-128-after-nccn-expands-anktiva-bladde\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-128-after-nccn-expands-anktiva-bladde","article_id":"2621876759","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-128-after-nccn-expands-anktiva-bladde","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621876759","pubTimestamp":1774030444,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In March 2026, ImmunityBio reported that the National Comprehensive Cancer Network updated its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease, extending beyond the therapy’s current U.S. FDA-approved indication in carcinoma in situ.\nThis guideline expansion effectively validates ANKTIVA’s role in a broader bladder cancer population, potentially influencing physician treatment choices and payer coverage...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4551":"寇图资本持仓","IBRX":"ImmunityBio, Inc.","BK4528":"SaaS概念","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4543":"AI","BK4585":"ETF&股票定投概念","AI":"C3.ai, Inc.","BK4587":"ChatGPT概念","BK4588":"碎股","BK4023":"应用软件"},"translate_title":"NCCN扩大ANKTIVA膀胱癌指南纳入范围后，ImmunityBio(IBRX)上涨12.8%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1.5,"AI":0.61,"AIYY":0.6},"content_text":"In March 2026, ImmunityBio reported that the National Comprehensive Cancer Network updated its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease, extending beyond the therapy’s current U.S. FDA-approved indication in carcinoma in situ. This guideline expansion effectively validates ANKTIVA’s role in a broader bladder cancer population, potentially influencing physician treatment choices and payer coverage policies even ahead of a formal label change. With ANKTIVA now recognized in NCCN guidelines for papillary-only disease, we’ll examine how this could influence ImmunityBio’s investment narrative. The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementImmunityBio Investment Narrative RecapTo own ImmunityBio, you need to believe ANKTIVA can evolve from a single approved bladder cancer drug into a broader IL‑15–based platform while the company narrows sizeable losses. The NCCN guideline expansion supports ANKTIVA’s use in papillary‑only disease but does not change that the key near term catalyst is the FDA decision on the papillary sBLA, and the biggest risk remains clinical and regulatory concentration in a single commercial asset. Among recent updates, the March 13 resubmission of the sBLA for ANKTIVA plus BCG in papillary‑only NMIBC ties most directly to the NCCN move. The guideline change leans on the same QUILT‑3.032 Cohort B data and arrives as the FDA reviews ImmunityBio’s new filing, so investors are watching whether real world physician uptake and payer coverage in this grey zone align with any eventual label decision. Yet despite the apparent validation, investors should be aware that the company still faces concentrated regulatory and reimbursement risk if ANKTIVA adoption in papillary disease... Read the full narrative on ImmunityBio (it's free!)ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and a $786.9 million earnings increase from -$351.4 million.Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 53% upside to its current price.Exploring Other PerspectivesIBRX 1-Year Stock Price Chart Some of the lowest estimate analysts were already cautious, assuming revenue of about US$895.3 million and earnings of roughly US$418.7 million by 2029, and they focus on the possibility that single arm data and country by country approvals for ANKTIVA plus checkpoint inhibitors in lung cancer may not scale as easily as bulls expect, so it is worth considering how the new bladder cancer guideline update might shift both optimistic and pessimistic views from here.Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth over 4x more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.Curious About Other Options?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Find 49 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}